Antioxidants and other pharmacological treatments for Friedreich ataxia.

Antioxidants and other pharmacological treatments for Friedreich ataxia. Kearney M, Orrell RW, Fahey M, Pandolfo M. Cochrane Database of Systematic Reviews 2012, Issue 4. Art. No.: CD007791. DOI: 10.1002/14651858.CD007791.pub3.

Keywords: Friedreich ataxia, efficacy of antioxidants, pharmacological treatments, idebenone treatment, compared to placebo.

Structural and Functional Studies of the Mitochondrial Cysteine Desulfurase from Arabidopsis thaliana.

Structural and Functional Studies of the Mitochondrial Cysteine Desulfurase from Arabidopsis thaliana. Valeria R. Turowski, Maria V. Busi, and Diego F. Gomez-Casati. Mol. Plant first published online April 17, 2012 doi:10.1093/mp/sss037

Keywords: AtNfs1, Arabidopsis thaliana, bacterial cysteine desulfurases, NifS, IscS, Fe–S cluster assembly, IscS, Arabidopsis frataxin (AtFH), plant mitochondria.

Movement disorders: Interferon-γ shows promise in a mouse model of Friedreich ataxia

Movement disorders: Interferon-γ shows promise in a mouse model of Friedreich ataxia. Tomassini et al., Nature Reviews Neurology , | doi:10.1038/nrneurol.2012.74

Idebenone for the treatment of Friedreich´s ataxia

Now in Catalonia (Spain), the Idebenone is out of the National Health System (CatSalut), so far, the doctors could prescribe it, and the patients did not pay for the Idebenone , within the context of the current crisis the cuts are tremendous , and the Idebenone also was hit.
To achieve this, they shield in a rigorous scientific studies based on standard evaluation methodologies .... but help them to achieve their goals, stop paying for idebenone!. With this evaluation methodologies the studies selection and the graded are terrible, only those with bad results are considered right....and without listening the advices of the doctors experts in FA.

Gómez D, Paladio N. Idebenona per al tractament de l‟atàxia de Friedreich. Barcelona: Agència d‟Informació, Avaluació i Qualitat en Salut. Servei Català de la Salut. Departament de Salut. Generalitat de Catalunya; 2012.

Full text PDF ( English Abstract on page 9 )

363 Cardiac effect of high doses idebenone therapy compared to low doses in patients with friedreich ataxia

363 Cardiac effect of high doses idebenone therapy compared to low doses in patients with friedreich ataxia. D. Velasco Sanchez, J. Thérien, M. Vanasse, N. Dahdah, A. Fournier. Montréal, QuébecCanadian Journal of Cardiology
Volume 27, Issue 5, Supplement , Pages S192-S193, September 2011

Keywords: Heart involvement in Friedreich's ataxia (FRDA), progressive hypertrophic cardiomyopathy, idebenone, high dose idebenone (Hi-IDB), low dose of idebenone (Lo-IDB), paediatric FDRA patients, clinical and echocardiographic data -systolic and diastolic function, left ventricular wall thickness and mass index (LVMi), statistically significant LVMi reduction, improved mitral deceleration time with Hi-IDB.

Friedreich’s Ataxia and Gait Changes through Participation in Therapeutic Horseback Riding

Friedreich’s Ataxia and Gait Changes through Participation in Therapeutic Horseback Riding. Katherine J. Gilliland and Adam C. Knight Department of Kinesiology, Mississippi State University, Mississippi State, Mississippi. Clinical Kinesiology 66(1); Spring, 2012

Keywords: gait analysis, equine assisted therapy, neurological disorder, therapeutic horseback riding, Friedreich’s Ataxia (FA).

Retrospective study of the effects of inpatient rehabilitation on improving and maintaining functional independence in people with Friedreich ataxia.

Retrospective study of the effects of inpatient rehabilitation on improving and maintaining functional independence in people with Friedreich ataxia. Sarah C. Milne, Emma J. Campagna, Louise A. Corben, Martin B. Delatycki, Kwong Teo, Andrew J. Churchyard, Terry P. Haines. Archives of Physical Medicine and Rehabilitation , 05 April 2012 (doi: 10.1016/j.apmr.2012.03.026).

Keywords: Friedreich ataxia, rehabilitation, intervention, Functional Independence Measure, outcome

"Habitual intake of dietary flavonoids and risk of Parkinson disease"

"Habitual intake of dietary flavonoids and risk of Parkinson disease"; X. Gao, A. Cassidy, M.A. Schwarzschild, E.B. Rimm, and A. Ascherio; Neurology WNL.0b013e31824f7fc4; published online ahead of print 4 April 2012; DOI:10.1212/WNL.0b013e31824f7fc4;

"Parkinson's disease is a neurological disease very different from the FA, but this statistical study shows what people have known since long time, the Flavonoids have a slight neuroprotective effect. It may be interesting to add these products to our diet, are harmless and also much more pleasant than the pills."

Explanation in simple terms:
Eating Berries May Lower Men's Parkinson's Risk, www.medicalnewstoday.com. Article Date: 06 Apr 2012

Does chromatin modulation provide the first wet biomarker for Huntington's disease?

Does chromatin modulation provide the first wet biomarker for Huntington's disease?. Reilmann, R. (2012), Mov. Disord., 27: 473. doi: 10.1002/mds.24914

No abstract is available for this article.

Iron Efflux from Astrocytes Plays a Role in Remyelination

Iron Efflux from Astrocytes Plays a Role in Remyelination. Katrin Schulz,
Antje Kroner, and Samuel David. The Journal of Neuroscience, 4 April 2012, 32(14): 4841-4847; doi: 10.1523/​JNEUROSCI.5328-11.2012

Centre for Research in Neuroscience, The Research Institute of the McGill University Health Center, Montreal, Québec H3G 1A4, Canada

Keywords: iron, myelination, astrocytes, remyelination, ferroportin (Fpn), microglia, cytokines (TNF-α and IL-1β), FGF-2, IL-1β, IGF-1, TNF-α.